We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

Z:NASDAQZillow Group, Inc. Analysis

Data as of 2026-05-12 - not real-time

$40.44

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The stock is trading just above its 20‑day SMA (≈44) and marginally above the 50‑day SMA, while the 200‑day SMA remains far higher (≈65), indicating a long‑term downtrend. RSI sits at 38, suggesting modest oversold pressure, but the MACD is bearish with the histogram in negative territory. Volatility is elevated at over 42% (30‑day) and beta exceeds 1.2, pointing to a price that swings sharply with the market.
Fundamental and news catalysts: Revenue grew 18% YoY and rentals are projected to rise ~30% in 2026, bolstered by a new AI model rollout and a strategic Preview+Realtor.com partnership. However, the current price (≈$40.44) sits above the DCF fair value ($37.19) and the PE ratio (162×) dwarfs the industry average (≈17×), signaling overvaluation on earnings. Forward‑PE improves to ~13× and analysts’ median target is $62.5, implying a sizable upside if growth materializes. Ongoing class‑action investigations add a legal‑risk overlay.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near immediate support (~$40.3) with limited upside to $48.4 resistance
  • Bearish MACD and neutral trend despite modest RSI oversold signal
  • Q2 revenue guidance (≈$750‑$765M) fell short of market expectations

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (18% YoY) and projected 30% rentals expansion
  • Forward PE (~13×) aligns with peers, suggesting valuation compression
  • Analyst median target (~$62.5) implies ~50% upside from current levels

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strategic AI deployment and expanded platform services could sustain growth
  • High historical volatility and beta keep price sensitivity elevated
  • Potential legal exposure from class‑action investigation adds uncertainty

Key Metrics & Analysis

Financial Health

Revenue Growth18.40%
Profit Margin2.27%
P/E Ratio161.8
ROE1.33%
ROA0.15%
Debt/Equity9.73
P/B Ratio2.0
Op. Cash Flow$464.0M
Free Cash Flow$285.5M
Industry P/E17.0

Technical Analysis

TrendNeutral
RSI38.0
Support$40.28
Resistance$48.44
MA 20$44.29
MA 50$43.58
MA 200$65.11
MACDBearish
VolumeIncreasing
Fear & Greed Index87.98

Valuation

Fair Value$37.19
Target Price$64.67
Upside/Downside59.91%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.30
Volatility42.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.